Potential barriers to reverse cascade screening combined with universal cholesterol screening for paediatric familial hypercholesterolemia: focus on second-degree relatives of a proband

Abstract

Aim: Familial hypercholesterolaemia (FH), an autosomal-dominant disorder, requires early diagnosis to prevent atherosclerosis in children and coronary artery disease (CAD) in their parents. This study aimed to evaluate the effectiveness and barriers of reverse cascade screening (RCS) combined with universal cholesterol screening (UCS) for paediatric FH.

Methods: We performed RCS combined with UCS for paediatric FH between January 2018 and July 2023. Family pedigree was evaluated in second-degree relatives, using a child with a genetic diagnosis of FH as the proband. Based on the 2022 Japan Atherosclerosis Society clinical guidelines, cases with suspected FH were classified into four categories: “Definite”, “Probable”, “Possible”, or “Unlikely”. Those who did not complete the diagnostic process were evaluated based on the reasons, including challenges such as “Untested lipids in children”, “Bereavement”, “CAD with unspecified details”, “Dyslipidaemia with unspecified low-density lipoprotein cholesterol (LDL-C) levels”, and “No information on CAD or dyslipidaemia”.

Results: Of 252 patients suspected of having FH, 94 completed the diagnostic process. Among them, 49 were classified as “Definite” FH cases, predominantly among first-degree relatives. In contrast, 158 patients did not complete the diagnostic process, with the most common barriers being “Dyslipidaemia with unspecified LDL-C levels” and “No information on CAD or dyslipidaemia”, particularly among second-degree relatives.

Conclusion: RCS combined with UCS for paediatric FH using genetic testing is effective for the early diagnosis of FH in asymptomatic cases. However, addressing barriers that hinder FH diagnosis, such as difficulties in approaching second-degree relatives, is critical for improving diagnosis rates.

Keywords

familial hypercholesterolemia / reverse cascade screening / universal cholesterol screening / low-density lipoprotein cholesterol / genetic testing / cardiovascular disease / paediatric screening

References

[1] Hu P,Stevens CAT.Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis.Circulation2020;141:1742-59

[2] Gulizia MM,Abrignani MG.POSTER InvestigatorsPrevalence of familial hypercholesterolaemia (FH) in italian patients with coronary artery disease: the POSTER study.Atherosclerosis2020;308:32-8

[3] Sturm AC,Gidding SS.Convened by the Familial Hypercholesterolemia FoundationClinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel.J Am Coll Cardiol2018;72:662-80

[4] Gidding SS,Groselj U.Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations.Eur J Prev Cardiol2022;29:2301-11

[5] McKay AJ,Humphries SE,Ray KK.Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: a cost-utility analysis.Atherosclerosis2018;275:434-43

[6] Brett T,Gidding S.Screening for familial hypercholesterolaemia in primary care: time for general practice to play its part.Atherosclerosis2018;277:399-406

[7] Tada H,Nomura A.Prognostic impact of cascade screening for familial hypercholesterolemia on cardiovascular events.J Clin Lipidol2021;15:358-65

[8] Lokkesmoe R.The role of reverse cascade screening in children with familial hypercholesterolemia: a literature review and analysis.Curr Atheroscler Rep2024;26:427-33

[9] Kusters DM,Kastelein JJ.Carotid intima-media thickness in children with familial hypercholesterolemia.Circ Res2014;114:307-10

[10] Matsunaga K,Ying Fu H.Universal screening for familial hypercholesterolemia in children in Kagawa, Japan.J Atheroscler Thromb2022;29:839-49 PMCID:PMC9174094

[11] Fu HY,Inoue T.Improved efficiency of the clinical diagnostic criteria for familial hypercholesterolemia in children: a comparison of the Japan atherosclerosis society guidelines of 2017 and 2022.J Atheroscler Thromb2024;31:1048-57 PMCID:PMC11224690

[12] Harada-Shiba M,Ohmura H.Guidelines for the diagnosis and treatment of adult familial hypercholesterolemia 2022.J Atheroscler Thromb2023;30:558-86 PMCID:PMC10164595

[13] Harada-Shiba M,Sugiyama D.Guidelines for the diagnosis and treatment of pediatric familial hypercholesterolemia 2022.J Atheroscler Thromb2023;30:531-57 PMCID:PMC10164603

[14] Tada H,Nomura A.Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease.J Clin Lipidol2018;12:1436-44

[15] Yamamoto T,Ondo Y.Challenges in detecting genomic copy number aberrations using next-generation sequencing data and the eXome Hidden Markov Model: a clinical exome-first diagnostic approach.Hum Genome Var2016;3:16025 PMCID:PMC4989049

[16] Lee C,Bangash H,Kullo IJ.New case detection by cascade testing in familial hypercholesterolemia: a systematic review of the literature.Circ Genom Precis Med2019;12:e002723 PMCID:PMC9875692

[17] Ibarretxe D,Feliu A,Masana L.Detecting familial hypercholesterolemia earlier in life by actively searching for affected children:the DECOPIN project.Atherosclerosis2018;278:210-6

[18] Matsunaga K,Yamashita S.A cost-effectiveness analysis for the combination of universal screening at 9-10 years old and reverse cascade screening of relatives for familial hypercholesterolemia in Japan.J Atheroscler Thromb2025;32:000-000

[19] Wilemon KA,Aguilar-Salinas C.Representatives of the Global Familial Hypercholesterolemia CommunityReducing the clinical and public health burden of familial hypercholesterolemia: a global call to action.JAMA Cardiol2020;5:217-29

[20] Cox E,Saramago P.Challenges and opportunities for identifying people with familial hypercholesterolemia in the UK: evidence from the national FH PASS database.J Clin Lipidol2024;18:e1046-54

[21] Campbell-Salome G,Masnick MF.Developing and optimizing innovative tools to address familial hypercholesterolemia underdiagnosis: identification methods, patient activation, and cascade testing for familial hypercholesterolemia.Circ Genom Precis Med2021;14:e003120 PMCID:PMC7892261

[22] Lentz M,Zhang X.Cascade screening for familial hypercholesterolemia from pediatric index cases diagnosed through universal screening.J Clin Lipidol2024;18:e620-4

[23] Monaco A,De Cola P,Palmer K.Information and communication technology for increasing healthy ageing in people with non-communicable diseases: identifying challenges and further areas for development.Aging Clin Exp Res2019;31:1689-93 PMCID:PMC6825021

[24] Osei J,Otchere B.A scoping review of electronic health records-based screening algorithms for familial hypercholesterolemia.JACC Adv2024;3:101297

[25] Page C,Wang H.A comparison of the Netherlands, Norway and UK familial hypercholesterolemia screening programmes with implications for target setting and the UK’s NHS long term plan.PLOS Glob Public Health2023;3:e0001795 PMCID:PMC10128934

[26] Reeskamp LF,Schonck WAM.Familial hypercholesterolemia detection through machine learning algorithms: a low-hanging fruit.JACC Adv2024;3:101181 PMCID:PMC11450937

[27] Baldry E,MacFarlane I.Outcomes from a pilot genetic counseling intervention using motivational interviewing and the extended parallel process model to increase cascade cholesterol screening.J Genet Couns2022;31:164-75